Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenue	$ 5,609	$ 832
Operating expenses:
Cost of sales	554	339
Research and development	67,301	70,123
Selling, general and administrative	28,367	31,515
Total operating expenses	96,222	101,977
Loss from operations	(90,613)	(101,145)
Royalty income from gain on sale of oncology business	0	2,704
Interest income, net	8,091	694
Other income, net	1,504	2,973
Net loss	$ (81,018)	$ (94,774)
Net (loss) income per share - basic (in usd per share)	$ (1.47)	$ (1.74)
Net (loss) income per share - diluted (in usd per share)	$ (1.47)	$ (1.74)
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - basic (in shares)	55,265,390	54,555,467
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - diluted (in shares)	55,265,390	54,555,467
Product revenue, net
Revenues:
Total revenue	$ 5,609	$ 832